For example, increased SPARC expression is strongly associated with tumor progression in gliomas and melanomas [25, 26], while some studies have reported SPARC as a tumor suppressor in neuroblastomas as well as ovarian and colorectal cancers [27–29]. Here, SPARC is linked to neoplasm.